The potential role of octreotide in the treatment of diabetic retinopathy

Treatments in Endocrinology

Volumn 4, Issue 4, 2005, Pages 199-203

  Grant, Maria B ^a   Caballero Jr , Sergio ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Department of Anesthesiology Pharmacology and Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; INSULIN; L 779976; OCTREOTIDE; SEGLITIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; THROMBOMODULIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENDOCRINOLOGY; ENDOTHELIUM CELL; GROWTH HORMONE RELEASE; HUMAN; LASER COAGULATION; NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; TREATMENT FAILURE; VISUAL ACUITY;

ANIMALS; CELLS, CULTURED; CLINICAL TRIALS; DIABETIC RETINOPATHY; HUMAN GROWTH HORMONE; HUMANS; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; OCTREOTIDE; SOMATOSTATIN;

EID: 23744444437     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200504040-00001     Document Type: Article

References (28)

1. Cunha-Vaz J. Lowering the risk of visual impairment and blindness. Diabet Med 1998; 15 Suppl. 4: S47-50
2. Grant MB, Russell B, Fitzgerald C, et al. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes 1986; 35 (4): 416-20
3. Limb GA, Chignell AH, Green W, et al. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 1996; 80 (2): 168-73
4. Poulsen JE. The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 1953; 2: 7-12
5. Boehm BO, Lang GK, Jehle PM, et al. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001; 33 (5): 300-6
6. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors in the fed and fasted states. J Clin Endocrinol Metab 1982; 55 (5): 999-1002
7. Alzaid AA, Dinneen SF, Melton LJ 3rd, et al. The role of growth hormone in the development of diabetic retinopathy. Diabetes Care 1994; 17 (6): 531-4
8. Hyer SL. Growth hormone suppression in diabetic retinopathy [abstract]. Diabetologia 1987; 30 (7): 534A
9. Kohner EM, Oakley NW. Diabetic retinopathy. Metabolism 1975; 24 (9): 1085-102
10. Shumak SL, Grossman LD, Chew E, et al. Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study. Clin Invest Med 1990; 13 (5): 287-92
11. Merimee TJ. Metabolic and clinical studies in growth hormone deficient dwarfs: a ten year follow-up. N Engl J Med 1978; 298: 1217-22
12. Chantelau E, Eggert H, Seppel T, et al. Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac's syndrome. Br J Ophthalmol 1997; 81 (2): 169-70
13. Chantelau E. Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 1998; 82 (7): 725-30
14. Daneman D, Lobes LA, Becker DJ, et al. Diabetic retinopathy in Mauriac's syndrome: paradoxical deterioration with improved metabolic control. Retina 1981; 1 (2): 84-7
15. Hyer SL, Sharp PS, Brooks RA, et al. Serum IGF-1 concentration in diabetic retinopathy. Diabet Med 1988; 5 (4): 356-60
16. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998; 39 (2): 233-52
17. Navascures I, Gil J, Pascau C, et al. Effect of a long-acting somatostatin derivative SMS 201-995 (Sandostatin®) on glucose homeostasis in type I diabetes mellitus. Horm Res 1988; 29: 92-4
18. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept 1993; 48 (1-2): 267-78
19. Davis MI, Wilson SH, Grant MB. The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors. Horm Metab Res 2001; 33 (5): 295-9
20. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20 (3): 157-98
21. Yang L, Berk SC, Rohrer SP, et al. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A 1998; 95 (18): 10836-41
22. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276 (5319): 1706-9
23. Averbukh E, Halpert M, Yanko R, et al. Octreotide, a somatostatin analogue, fails to inhibit hypoxia-induced retinal neovascularization in the neonatal rat. Int J Exp Diabetes Res 2000; 1 (1): 39-47
24. Hyer SL, Sharp PS, Brooks RA, et al. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion and diabetics with retinopathy. Acta Endocrinol (Copenh) 1989; 120 (2): 187-94
25. Kirkegaard C, Norgaard K, Snorgaard O, et al. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in type I (insulin-dependent) diabetes mellitus. Acta Endocrinol (Copenh) 1990; 122 (6): 766-72
26. Mallet B, Vialettes B, Haroche S, et al. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes Metab 1992; 18 (6): 438-44
27. Clemens A, Klevesath MS, Hofmann M, et al. Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus. Metabolism 1999; 48 (10): 1236-40
28. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000; 23 (4): 504-9